Background Gastrointestinal stromal tumor (GIST) is known for its wide variability in biological behaviors and it is difficult to predict its malignant potential. The aim of this study is to ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

The molecular background of gastrointestinal stromal tumors (GISTs) has been investigated through genome and transcriptome studies, but the proteomic profile of these tumors has not yet been ...

Colonic schwannomas and gastrointestinal stromal tumors (GISTs) are rare types of tumors that can occur in the gastrointestinal tract. Schwannomas originate from Schwann cells, which are ...

A multidisciplinary approach is crucial for managing GIST, involving surgical, medical, and potentially targeted therapies. For patients with gastrointestinal stromal tumors with liver metastases, ...

Among patients with gastrointestinal stromal tumors (GIST), the most common mesenchymal tumor of the GI tract, treatment with bezuclastinib (CGT9486) and Sutent (sunitinib) demonstrated acceptable ...

GSK announced that it has agreed to terms to acquire IDRx, a clinical-stage biopharmaceutical company focused on developing precision therapeutics for gastrointestinal stromal tumors (GIST). According ...

GSK has announced that it will be expanding its gastrointestinal (GI) cancer pipeline by acquiring IDRx in a deal worth up to $1.15bn ... being developed as a first- and second-line therapy for ...

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST ... clinical-stage biopharmaceutical company dedicated ...

The tyrosine kinase inhibitor (TKI) is designed to be a first- and second-line therapy for gastrointestinal stromal tumors (GIST) by hitting all key KIT mutations, something that gives the asset ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage ... gastrointestinal stromal tumors or GIST.